Skip to main content
Core One Labs Inc. logo

Core One Labs Inc. — Investor Relations & Filings

Ticker · COOL ISIN · CA21872J3073 LEI · 967600KYL2KZ0CXTJH21 CSE Professional, scientific and technical activities
Open in API
Filings indexed 192 across all filing types
Latest filing 2024-06-05 Investor Presentation
Country CA Canada
Listing CSE COOL

About Core One Labs Inc.

https://core1labs.com

Core One Labs Inc. is a biotechnology research and technology enterprise focused on the development and commercialization of psychedelic medicines. The company's core strategy involves bringing these therapeutic compounds to market through the utilization of novel delivery systems and integration with psychedelic assisted psychotherapy protocols. Core One Labs conducts life sciences research, including the biosynthesis of various psychedelic compounds such as DMT. The company collaborates with medical professionals and licensed producers to facilitate the provision of treatments, prescription fulfillment, and the sale of related products.

Recent filings

Filing Released Lang Actions
Other material contracts - English.pdf
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Fourth Quarter 2024 Results' by Stingray Group Inc. It contains forward-looking statements, business descriptions, market updates, and investment highlights. The content is typical of an investor presentation focusing on financial results, business segments, growth strategies, and market positioning. It does not contain full financial statements or detailed management discussion and analysis, but rather a comprehensive overview aimed at investors. The length (15,000 characters) and the nature of the content (slides with business and financial highlights) align with an Investor Presentation rather than an Earnings Release or Annual Report. Therefore, the document is best classified as an Investor Presentation (IP).
2024-06-05 English
Other material contracts - English.pdf
Merger & Acquisition Classification · 100% confidence The document is titled 'SHARE PURCHASE AGREEMENT' and details the terms and conditions under which shareholders of Vocan Biotechnologies Inc. sell their shares to Core One Labs Inc. It includes definitions, purchase and sale terms, consideration shares, warrants, and legal provisions typical of a share purchase agreement. There is no indication that this is a financial report, earnings release, or regulatory filing. Instead, it is a legal contract related to a merger or acquisition transaction. Therefore, the document fits the category of Merger & Acquisition (MA) filings, which include merger communications and agreements related to acquisitions.
2024-06-05 English
Other material contracts - English.pdf
Merger & Acquisition Classification · 100% confidence The document is titled 'PURCHASE AGREEMENT' and details terms of a share purchase transaction between Awakened Biosciences Inc. and Core One Labs Inc., including definitions, purchase and sale terms, and securities exemptions. It is a legal contract related to a merger or acquisition transaction rather than a financial report, regulatory filing, or announcement of voting results. The content is consistent with a merger or acquisition agreement rather than other filing types such as Annual Report, Earnings Release, or Capital Update. Therefore, the document fits best under the 'Merger & Acquisition' category, which covers merger, acquisition, and tender-offer filings including purchase agreements.
2024-06-05 English
Other material contracts - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Share Purchase Agreement' and details the terms and conditions of a share purchase transaction between GMP Drug Inc., its shareholders (Vendors), and Core One Labs Inc. (Purchaser). It includes definitions, purchase and sale terms, issuance of shares as consideration, and references to securities laws and exemptions. This is a legal agreement related to a transaction involving share ownership and capital structure changes. It is not a financial report, earnings release, or regulatory filing announcement. The content fits the category of a capital or financing update, specifically concerning a share purchase transaction and issuance of shares as consideration. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-06-05 English
Other material contracts - English.pdf
Merger & Acquisition Classification · 100% confidence The document is titled 'SHARE PURCHASE AGREEMENT' and details the terms and conditions of a share purchase transaction between shareholders of Akome Biotech Ltd. and Core One Labs Inc. It includes definitions, purchase and sale terms, and covenants related to the transaction. This is a legal agreement related to a merger or acquisition transaction rather than a financial report, regulatory filing, or announcement of voting results. The content aligns with documentation typically filed under merger and acquisition activities. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length and detail confirm it is the agreement itself, not a brief announcement or summary.
2024-06-05 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the extension of a non-brokered private placement financing by Core One Labs Inc. It discusses the approval from the Canadian Securities Exchange to extend the closing date of the private placement and provides background information about the company and its business. There are no financial statements, detailed financial results, or regulatory filings such as annual or quarterly reports. The content focuses on capital raising activity and financing updates. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is 5246 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2024-05-16 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.